Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

Interim Management Statement

11 Apr 2012 07:00

RNS Number : 0556B
BATM Advanced Communications Ld
11 April 2012
 



 

 

 

11 April 2012

 

BATM Advanced Communications Limited

Interim Management Statement

BATM Advanced Communications Limited ("BATM" or the "Company") (LSE: BVC), a leading designer and producer of telecom systems and medical laboratory diagnostic and sterilisation systems, is today issuing its Interim Management Statement for the period from 1 January 2012 to 31 March 2012.

Current trading update 

Total revenues in the first quarter of 2012 (Q1) were $24.9 million, slightly ahead of our plan, and compared with $27.4 million on a like for like basis for the equivalent period in 2011, which excludes revenues from the discontinued legacy telecom business.

 

During the first quarter of the year the sales mix was 52% from the Telecoms division and 48% from the Medical division compared to 66% and 34% respectively in the first quarter of 2011. Gross margin was lower during the first quarter of 2012 than over the same period of 2011 as a result of a higher mix of Medical sales but nonetheless met the company's internal targets. Significant improvement in gross margin was achieved in the Medical division over the same period last year despite the fact that we are still in the early stages of production in our diagnostic division.

 

Financial position 

The Company's balance sheet remains strong and at March 31 the effective cash balance stood at $42.7 million, a decrease of $4.2 million compared to the position at December 31 2011, mainly as a result of repayment of a long term loan that is expected to generate a one off gain of approximately $0.7 million.

 

Telecom Division

Our Telecom division is, following its re-organisation, making progress in line with our previous guidance. New customers are being won worldwide as the division focuses on being a key supplier to next generation telecoms networks.

 

Medical Division

The Medical division continues to make significant progress in gaining validation for its products and in growing its market presence. This progress can be evidenced by our recent announcement that the Company had received CE certification for its Detect HIV 4th Generation Total Screening Kit, which proved 100% accurate in independent testing.

 

The improved margins that we reported have been demonstrated in all three areas of operations: diagnostics, sterilisation and distribution. This is in line with our long term target to increase our operating margins in the Medical division to the levels of our Telecom division.

 

 

Outlook BATM has achieved its goals for the first quarter and significant progress has been made in the Medical Division.

 

Despite the challenging commercial macro environment we believe we are on track to achieve our strategic, operating and financial targets for the full year and remain cautiously optimistic regarding the outlook for both of our divisions in the medium term.

 

 

- Ends -

 

Enquiries

 

BATM Advanced Communications +972 9866 2525   

Dr Zvi Marom, Chief Executive

Ofer Bar-Ner, CFO

 

Threadneedle Communications 020 7653 9850

Josh Royston / Graham Herring

 

FinnCap 020 7220 0500

Marc Young

 

Shore Capital 020 7408 4090 

Pascal Keane

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBUGDSCGBBGDG
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.